proxyvotesnow.com

Home › Companies › NewAmsterdam Pharma Company N.V. › 2024-2025

NewAmsterdam Pharma Company N.V. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and NewAmsterdam Pharma Company N.V.’s Form 8-K, filed 2025-06-06 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 22Reported items
  • 118Asset managers
  • 1,113Fund votes
  • 2025-06-04Meeting date

Proxy season: 2024-2025 2025-2026

Explore NewAmsterdam Pharma Company N.V. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by NewAmsterdam Pharma Company N.V.

These tallies are NewAmsterdam Pharma Company N.V.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-06 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

NewAmsterdam Pharma Company N.V. — official shareholder meeting results, meeting held 2025-06-04
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Proposal 2. The Company's shareholders approved the discharge from liability for the Company's directors with respect to the performance of their duties during the fiscal year ended December 31, 2024. 79,671,21029,66449,158 --3,844,852 Majority: yes
Proposal 3. The Company's shareholders approved the appointment of and instruction to Deloitte Accounts B.V. 83,569,3255,79819,761 ---- Majority: yes
Proposal 4. The Company's shareholders ratified the selection of Deloitte Accountants B.V. 83,557,64217,63619,606 ---- Majority: yes
Elect Director: Wouter Joustra 79,415,918313,93720,177 --3,844,852 Majority: yes
Elect Director: Mark C. McKenna 79,264,690465,76619,576 --3,844,852 Majority: yes
Elect Director: Adele Gulfo 79,603,736126,71919,577 --3,844,852 Majority: yes
Elect Director: Michael Davidson, M.D. 70,484,2709,247,81917,943 --3,844,852 Majority: yes
Elect Director: James N. Topper 70,539,2959,190,89419,843 --3,844,852 Majority: yes
Proposal 7. The Company's shareholders approved the extension of authorization for the Board to acquire ordinary shares and depository receipts for ordinary shares in the Company's capital. 71,365,53312,226,8582,493 ---- Majority: yes
Proposal 8. The Company's shareholders approved the 2024 compensation of the Company's named executive officers by a non-binding, advisory ("Say-on-Pay") vote. 78,601,3961,126,55122,085 --3,844,852 Majority: yes

Source: NewAmsterdam Pharma Company N.V., Form 8-K, filed with the SEC on 2025-06-06 — read the filing on EDGAR.

How asset managers voted at the NewAmsterdam Pharma Company N.V. 2024-2025 meeting

Each item below shows how the 118 asset managers that disclosed a NewAmsterdam Pharma Company N.V. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of NewAmsterdam Pharma Company N.V.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Non-binding, advisory vote to approve the 2024 compensation of named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 78,601,396AGAINST: 1,126,551

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Proposal 8. The Company's shareholders approved the 2024 compensation of the Company's named executive officers by a non-binding, advisory ("Say-on-Pay") vote.”): 78,601,396 for, 1,126,551 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,169,291 outstanding shares: 70% for, 1% against (71% of the company cast a for/against vote).

The 117 asset managers below cast 99.4% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 99.4%
FOR: 99.4%AGAINST: 0.6%ABSTAIN: 0.0%NOT VOTED: 0.0%
Largest asset managers voting on “Non-binding, advisory vote to approve the 2024 compensation of named executive officers.” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Frazier Life Sciences Management, L.P.16,116,4180 00For
Capital Group11,135,2590 00For
FCPM III SERVICES B.V.10,632,1130 00For
Bain Capital Life Sciences Investors, LLC10,473,9130 00For
RA CAPITAL MANAGEMENT, L.P.8,625,4980 00For
VIKING GLOBAL INVESTORS LP6,978,5340 00For
DEERFIELD MANAGEMENT COMPANY, L.P.5,237,5670 00For
Medicxi Ventures Management (Jersey) Ltd2,869,5650 00For
Wellington2,859,7970 00For
JENNISON ASSOCIATES LLC2,777,8500 00For
AllianceBernstein2,699,8020 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.2,504,8840 00For
Janus Henderson2,032,7000 00For
Vanguard1,904,6630 00For
PICTET ASSET MANAGEMENT SA1,678,9150 00For
Prudential/PGIM1,674,2200 00For
Cormorant Asset Management, LP1,504,8560 00For
Woodline Partners LP1,374,1770 00For
Aberdeen1,272,7760 00For
MAVERICK CAPITAL LTD873,6300 00For
NEW ECONOMY FUND787,9050 00For
TimesSquare Capital Management, LLC705,6500 00For
JPMorgan556,3720 00For
Fidelity555,8520 00For
Rock Springs Capital Management LP519,1490 00For

Showing the 25 largest of 117 asset managers. See all 117 in the interactive database.

2. Non-binding, advisory vote regarding frequency of future shareholders' advisory votes on the compensation of named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

12%ONE YEAR 61%1 YEAR 19%7%

The 110 asset managers below cast 100% of the shares they voted on this item FOR (10,729,005 for, 0 against).

FOR: 10,729,005 (12.0%)ABSTAIN: 16,048 (0.0%)ONE YEAR: 54,784,085 (61.2%)1 YEAR: 17,294,258 (19.3%)1YR: 6,650,136 (7.4%)1-YEAR: 650 (0.0%)NOT VOTED: 225 (0.0%)
Largest asset managers voting on “Non-binding, advisory vote regarding frequency of future shareholders' advisory votes on the compensation of n” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Frazier Life Sciences Management, L.P.00 00One Year
Capital Group00 001Yr
FCPM III SERVICES B.V.10,632,1130 00For
RA CAPITAL MANAGEMENT, L.P.00 00One Year
VIKING GLOBAL INVESTORS LP00 00One Year
DEERFIELD MANAGEMENT COMPANY, L.P.00 001 Year
Medicxi Ventures Management (Jersey) Ltd00 001 Year
Wellington00 001 Year
AllianceBernstein00 00One Year
JENNISON ASSOCIATES LLC00 001 Year
Janus Henderson00 00One Year
Vanguard00 00One Year
PICTET ASSET MANAGEMENT SA00 00One Year
Prudential/PGIM00 00One Year
Cormorant Asset Management, LP00 001 Year
Woodline Partners LP00 00One Year
Aberdeen00 00One Year
MAVERICK CAPITAL LTD00 001 Year
NEW ECONOMY FUND00 00One Year
TimesSquare Capital Management, LLC00 00One Year
Fidelity00 00One Year
Rock Springs Capital Management LP00 00One Year
AB DISCOVERY GROWTH FUND, INC.00 00One Year
Slate Path Capital LP00 00One Year
BNP Paribas Asset Management Holding S.A.00 00One Year

Showing the 25 largest of 110 asset managers. See all 110 in the interactive database.

3. Appointment of the following individuals as non-executive directors of the Company until the annual general meeting set forth next to their name: Adele Gulfo

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 79,603,736AGAINST: 126,719

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Elect Director: Adele Gulfo”): 79,603,736 for, 126,719 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,169,291 outstanding shares: 71% for, 0.2% against (71% of the company cast a for/against vote).

The 37 asset managers below cast 99.0% of the shares they voted on this item FOR (12,172,145 for, 115,421 against).

FOR 99%
FOR: 12,172,145 (98.9%)AGAINST: 115,421 (0.9%)ABSTAIN: 16,048 (0.1%)
Largest asset managers voting on “Appointment of the following individuals as non-executive directors of the Company until the annual general me” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group4,485,1230 00For
Vanguard1,895,3060 00For
Prudential/PGIM1,674,2200 00For
NEW ECONOMY FUND787,9050 00For
AllianceBernstein756,6130 00For
Aberdeen636,3880 00For
AB DISCOVERY GROWTH FUND, INC.473,0470 00For
Fidelity279,3490 00For
JPMorgan193,5040 00For
Equitable175,9490 00For
Principal153,0140 00For
First Trust132,2710 00For
Eaton Vance0115,421 00Against
Columbia Threadneedle107,4610 00For
FRANKLIN STRATEGIC SERIES92,3000 00For
American Century53,6540 00For
AMG FUNDS47,0000 00For
MERIDIAN FUND INC31,6400 00For
Global X29,7790 00For
Advisors' Inner Circle Fund III28,6250 00For
TIFF INVESTMENT PROGRAM28,5800 00For
BlackRock21,4900 00For
AIG/SunAmerica19,0930 00For
Brighthouse580 16,0480Abstain
ALGER FUNDS11,1640 00For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

4. Appointment of the following individuals as non-executive directors of the Company until the annual general meeting set forth next to their name: Mark McKenna

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 79,264,690AGAINST: 465,766

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Elect Director: Mark C. McKenna”): 79,264,690 for, 465,766 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,169,291 outstanding shares: 71% for, 0.5% against (71% of the company cast a for/against vote).

The 37 asset managers below cast 99.0% of the shares they voted on this item FOR (12,172,145 for, 115,421 against).

FOR 99%
FOR: 12,172,145 (98.9%)AGAINST: 115,421 (0.9%)ABSTAIN: 16,048 (0.1%)
Largest asset managers voting on “Appointment of the following individuals as non-executive directors of the Company until the annual general me” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group4,485,1230 00For
Vanguard1,895,3060 00For
Prudential/PGIM1,674,2200 00For
NEW ECONOMY FUND787,9050 00For
AllianceBernstein756,6130 00For
Aberdeen636,3880 00For
AB DISCOVERY GROWTH FUND, INC.473,0470 00For
Fidelity279,3490 00For
JPMorgan193,5040 00For
Equitable175,9490 00For
Principal153,0140 00For
First Trust132,2710 00For
Eaton Vance0115,421 00Against
Columbia Threadneedle107,4610 00For
FRANKLIN STRATEGIC SERIES92,3000 00For
American Century53,6540 00For
AMG FUNDS47,0000 00For
MERIDIAN FUND INC31,6400 00For
Global X29,7790 00For
Advisors' Inner Circle Fund III28,6250 00For
TIFF INVESTMENT PROGRAM28,5800 00For
BlackRock21,4900 00For
AIG/SunAmerica19,0930 00For
Brighthouse580 16,0480Abstain
ALGER FUNDS11,1640 00For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

5. Appointment of the following individuals as non-executive directors of the Company until the annual general meeting set forth next to their name: Wouter Joustra

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 79,415,918AGAINST: 313,937

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Elect Director: Wouter Joustra”): 79,415,918 for, 313,937 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,169,291 outstanding shares: 71% for, 0.3% against (71% of the company cast a for/against vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (12,287,566 for, 0 against).

FOR 99.8%
FOR: 12,287,566 (99.9%)ABSTAIN: 16,048 (0.1%)
Largest asset managers voting on “Appointment of the following individuals as non-executive directors of the Company until the annual general me” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group4,485,1230 00For
Vanguard1,895,3060 00For
Prudential/PGIM1,674,2200 00For
NEW ECONOMY FUND787,9050 00For
AllianceBernstein756,6130 00For
Aberdeen636,3880 00For
AB DISCOVERY GROWTH FUND, INC.473,0470 00For
Fidelity279,3490 00For
JPMorgan193,5040 00For
Equitable175,9490 00For
Principal153,0140 00For
First Trust132,2710 00For
Eaton Vance115,4210 00For
Columbia Threadneedle107,4610 00For
FRANKLIN STRATEGIC SERIES92,3000 00For
American Century53,6540 00For
AMG FUNDS47,0000 00For
MERIDIAN FUND INC31,6400 00For
Global X29,7790 00For
Advisors' Inner Circle Fund III28,6250 00For
TIFF INVESTMENT PROGRAM28,5800 00For
BlackRock21,4900 00For
AIG/SunAmerica19,0930 00For
Brighthouse580 16,0480Abstain
ALGER FUNDS11,1640 00For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

6. RATIFICATION OF THE SELECTION OF DELOITTE ACCOUNTANTS B.V. AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025 BY THE AUDIT COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 83,557,642AGAINST: 17,636

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Proposal 4. The Company's shareholders ratified the selection of Deloitte Accountants B.V.”): 83,557,642 for, 17,636 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,169,291 outstanding shares: 74% for, 0.1% against (75% of the company cast a for/against vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (12,287,566 for, 0 against).

FOR 99.8%
FOR: 12,287,566 (99.9%)ABSTAIN: 16,048 (0.1%)
Largest asset managers voting on “RATIFICATION OF THE SELECTION OF DELOITTE ACCOUNTANTS B.V. AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIR” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group4,485,1230 00For
Vanguard1,895,3060 00For
Prudential/PGIM1,674,2200 00For
NEW ECONOMY FUND787,9050 00For
AllianceBernstein756,6130 00For
Aberdeen636,3880 00For
AB DISCOVERY GROWTH FUND, INC.473,0470 00For
Fidelity279,3490 00For
JPMorgan193,5040 00For
Equitable175,9490 00For
Principal153,0140 00For
First Trust132,2710 00For
Eaton Vance115,4210 00For
Columbia Threadneedle107,4610 00For
FRANKLIN STRATEGIC SERIES92,3000 00For
American Century53,6540 00For
AMG FUNDS47,0000 00For
MERIDIAN FUND INC31,6400 00For
Global X29,7790 00For
Advisors' Inner Circle Fund III28,6250 00For
TIFF INVESTMENT PROGRAM28,5800 00For
BlackRock21,4900 00For
AIG/SunAmerica19,0930 00For
Brighthouse580 16,0480Abstain
ALGER FUNDS11,1640 00For

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

7. ADOPTION OF THE DUTCH STATUTORY ANNUAL ACCOUNTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024.

CORPORATE GOVERNANCE

100% fund support · no official result

FOR 99.8%

The 35 asset managers below cast 100% of the shares they voted on this item FOR (12,279,062 for, 0 against).

FOR: 12,279,062 (99.9%)ABSTAIN: 16,048 (0.1%)
Largest asset managers voting on “ADOPTION OF THE DUTCH STATUTORY ANNUAL ACCOUNTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024.” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group4,485,1230 00For
Vanguard1,895,3060 00For
Prudential/PGIM1,674,2200 00For
NEW ECONOMY FUND787,9050 00For
AllianceBernstein756,6130 00For
Aberdeen636,3880 00For
AB DISCOVERY GROWTH FUND, INC.473,0470 00For
Fidelity279,3490 00For
JPMorgan193,5040 00For
Equitable175,9490 00For
Principal153,0140 00For
First Trust132,2710 00For
Eaton Vance115,4210 00For
Columbia Threadneedle107,4610 00For
FRANKLIN STRATEGIC SERIES92,3000 00For
American Century53,6540 00For
AMG FUNDS47,0000 00For
MERIDIAN FUND INC31,6400 00For
Global X29,7790 00For
Advisors' Inner Circle Fund III28,6250 00For
TIFF INVESTMENT PROGRAM28,5800 00For
BlackRock21,4900 00For
AIG/SunAmerica19,0930 00For
Brighthouse580 16,0480Abstain
ALGER FUNDS11,1640 00For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

8. DISCHARGE FROM LIABILITY FOR THE COMPANY'S DIRECTORS WITH RESPECT TO THE PERFORMANCE OF THEIR DUTIES DURING THE FISCAL YEAR ENDED DECEMBER 31, 2024.

CORPORATE GOVERNANCEMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 79,671,210AGAINST: 29,664

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Proposal 2. The Company's shareholders approved the discharge from liability for the Company's directors with respect to the performance of their duties during the fiscal year ended December 31, 2024.”): 79,671,210 for, 29,664 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,169,291 outstanding shares: 71% for, 0.1% against (71% of the company cast a for/against vote).

The 35 asset managers below cast 100% of the shares they voted on this item FOR (12,279,062 for, 0 against).

FOR 99.8%
FOR: 12,279,062 (99.9%)ABSTAIN: 16,048 (0.1%)
Largest asset managers voting on “DISCHARGE FROM LIABILITY FOR THE COMPANY'S DIRECTORS WITH RESPECT TO THE PERFORMANCE OF THEIR DUTIES DURING TH” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group4,485,1230 00For
Vanguard1,895,3060 00For
Prudential/PGIM1,674,2200 00For
NEW ECONOMY FUND787,9050 00For
AllianceBernstein756,6130 00For
Aberdeen636,3880 00For
AB DISCOVERY GROWTH FUND, INC.473,0470 00For
Fidelity279,3490 00For
JPMorgan193,5040 00For
Equitable175,9490 00For
Principal153,0140 00For
First Trust132,2710 00For
Eaton Vance115,4210 00For
Columbia Threadneedle107,4610 00For
FRANKLIN STRATEGIC SERIES92,3000 00For
American Century53,6540 00For
AMG FUNDS47,0000 00For
MERIDIAN FUND INC31,6400 00For
Global X29,7790 00For
Advisors' Inner Circle Fund III28,6250 00For
TIFF INVESTMENT PROGRAM28,5800 00For
BlackRock21,4900 00For
AIG/SunAmerica19,0930 00For
Brighthouse580 16,0480Abstain
ALGER FUNDS11,1640 00For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

9. EXTENSION OF AUTHORIZATION FOR THE BOARD OF DIRECTORS TO ACQUIRE ORDINARY SHARES AND DEPOSITORY RECEIPTS FOR ORDINARY SHARES IN THE COMPANY'S CAPITAL.

CAPITAL STRUCTUREMajority of the votes cast: yes

85% Majority: yes · of votes cast

FOR 85%AGAINST 15%
FOR: 71,365,533AGAINST: 12,226,858

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Proposal 7. The Company's shareholders approved the extension of authorization for the Board to acquire ordinary shares and depository receipts for ordinary shares in the Company's capital.”): 71,365,533 for, 12,226,858 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,169,291 outstanding shares: 64% for, 11% against (75% of the company cast a for/against vote).

The 35 asset managers below cast 84% of the shares they voted on this item FOR (10,356,142 for, 1,938,968 against).

FOR 84%AGAINST 16%
FOR: 10,356,142 (84.2%)AGAINST: 1,938,968 (15.8%)
Largest asset managers voting on “EXTENSION OF AUTHORIZATION FOR THE BOARD OF DIRECTORS TO ACQUIRE ORDINARY SHARES AND DEPOSITORY RECEIPTS FOR O” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group4,485,1230 00For
Vanguard1,895,3060 00For
Prudential/PGIM1,674,2200 00For
NEW ECONOMY FUND787,9050 00For
AllianceBernstein0756,613 00Against
Aberdeen636,3880 00For
AB DISCOVERY GROWTH FUND, INC.0473,047 00Against
Fidelity262,42316,926 00For
JPMorgan193,5040 00For
Equitable0175,949 00Against
Principal0153,014 00Against
First Trust0132,271 00Against
Eaton Vance115,4210 00For
Columbia Threadneedle107,4610 00For
FRANKLIN STRATEGIC SERIES092,300 00Against
American Century053,654 00Against
AMG FUNDS47,0000 00For
MERIDIAN FUND INC31,6400 00For
Global X29,7790 00For
Advisors' Inner Circle Fund III28,6250 00For
TIFF INVESTMENT PROGRAM28,5800 00For
BlackRock021,490 00Against
AIG/SunAmerica019,093 00Against
Brighthouse16,1060 00For
ALGER FUNDS011,164 00Against

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

10. INSTRUCTION TO DELOITTE ACCOUNTANTS B.V. AS THE COMPANY'S EXTERNAL AUDITOR OF THE COMPANY'S DUTCH STATUTORY ANNUAL ACCOUNTS AND DUTCH STATUTORY BOARD REPORT FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATED

100% fund support · no official result

FOR 99.8%

The 35 asset managers below cast 100% of the shares they voted on this item FOR (12,279,062 for, 0 against).

FOR: 12,279,062 (99.9%)ABSTAIN: 16,048 (0.1%)
Largest asset managers voting on “INSTRUCTION TO DELOITTE ACCOUNTANTS B.V. AS THE COMPANY'S EXTERNAL AUDITOR OF THE COMPANY'S DUTCH STATUTORY AN” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group4,485,1230 00For
Vanguard1,895,3060 00For
Prudential/PGIM1,674,2200 00For
NEW ECONOMY FUND787,9050 00For
AllianceBernstein756,6130 00For
Aberdeen636,3880 00For
AB DISCOVERY GROWTH FUND, INC.473,0470 00For
Fidelity279,3490 00For
JPMorgan193,5040 00For
Equitable175,9490 00For
Principal153,0140 00For
First Trust132,2710 00For
Eaton Vance115,4210 00For
Columbia Threadneedle107,4610 00For
FRANKLIN STRATEGIC SERIES92,3000 00For
American Century53,6540 00For
AMG FUNDS47,0000 00For
MERIDIAN FUND INC31,6400 00For
Global X29,7790 00For
Advisors' Inner Circle Fund III28,6250 00For
TIFF INVESTMENT PROGRAM28,5800 00For
BlackRock21,4900 00For
AIG/SunAmerica19,0930 00For
Brighthouse580 16,0480Abstain
ALGER FUNDS11,1640 00For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

11. Reappointment of Michael Davidson M.D. as executive director and Dr. James N. Topper as non-executive director of the Company until the 2029 annual general meeting: James N. Topper

DIRECTOR ELECTIONS

91% fund support · no official result

FOR 91%9%

The 29 asset managers below cast 91% of the shares they voted on this item FOR (10,892,313 for, 1,089,254 against).

FOR: 10,892,313 (90.8%)AGAINST: 1,089,254 (9.1%)ABSTAIN: 16,048 (0.1%)
Largest asset managers voting on “Reappointment of Michael Davidson M.D. as executive director and Dr. James N. Topper as non-executive director” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group4,485,1230 00For
Vanguard1,895,3060 00For
Prudential/PGIM1,674,2200 00For
NEW ECONOMY FUND787,9050 00For
AllianceBernstein756,6130 00For
Aberdeen0636,388 00Against
AB DISCOVERY GROWTH FUND, INC.473,0470 00For
Fidelity279,3490 00For
Equitable175,9490 00For
Principal153,0140 00For
First Trust0132,271 00Against
Eaton Vance0115,421 00Against
Columbia Threadneedle107,4610 00For
FRANKLIN STRATEGIC SERIES092,300 00Against
American Century053,654 00Against
MERIDIAN FUND INC31,6400 00For
Global X29,7790 00For
Advisors' Inner Circle Fund III28,3110 00For
AIG/SunAmerica019,093 00Against
Brighthouse580 16,0480Abstain
ALGER FUNDS011,164 00Against
ALPS ETF Trust07,729 00Against
ALGER PORTFOLIOS06,809 00Against
Forethought Variable Insurance Trust6,7000 00For
State Street6,5740 00For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

12. Reappointment of Michael Davidson M.D. as executive director and Dr. James N. Topper as non-executive director of the Company until the 2029 annual general meeting: Michael Davidson

DIRECTOR ELECTIONS

91% fund support · no official result

FOR 91%9%

The 29 asset managers below cast 91% of the shares they voted on this item FOR (10,892,313 for, 1,089,254 against).

FOR: 10,892,313 (90.8%)AGAINST: 1,089,254 (9.1%)ABSTAIN: 16,048 (0.1%)
Largest asset managers voting on “Reappointment of Michael Davidson M.D. as executive director and Dr. James N. Topper as non-executive director” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group4,485,1230 00For
Vanguard1,895,3060 00For
Prudential/PGIM1,674,2200 00For
NEW ECONOMY FUND787,9050 00For
AllianceBernstein756,6130 00For
Aberdeen0636,388 00Against
AB DISCOVERY GROWTH FUND, INC.473,0470 00For
Fidelity279,3490 00For
Equitable175,9490 00For
Principal153,0140 00For
First Trust0132,271 00Against
Eaton Vance0115,421 00Against
Columbia Threadneedle107,4610 00For
FRANKLIN STRATEGIC SERIES092,300 00Against
American Century053,654 00Against
MERIDIAN FUND INC31,6400 00For
Global X29,7790 00For
Advisors' Inner Circle Fund III28,3110 00For
AIG/SunAmerica019,093 00Against
Brighthouse580 16,0480Abstain
ALGER FUNDS011,164 00Against
ALPS ETF Trust07,729 00Against
ALGER PORTFOLIOS06,809 00Against
Forethought Variable Insurance Trust6,7000 00For
State Street6,5740 00For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

13. REAPPOINTMENT OF JAMES N. TOPPER AS NON-EXECUTIVE DIRECTOR OF THE COMPANY UNTIL THE 2029 ANNUAL GENERAL MEETING.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%
FOR: 70,539,295AGAINST: 9,190,894

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Elect Director: James N. Topper”): 70,539,295 for, 9,190,894 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,169,291 outstanding shares: 63% for, 8% against (71% of the company cast a for/against vote).

The 9 asset managers below cast 99% of the shares they voted on this item FOR (301,505 for, 4,494 against).

FOR 99%
FOR: 301,505 (98.5%)AGAINST: 4,494 (1.5%)
Largest asset managers voting on “REAPPOINTMENT OF JAMES N. TOPPER AS NON-EXECUTIVE DIRECTOR OF THE COMPANY UNTIL THE 2029 ANNUAL GENERAL MEETIN” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
JPMorgan193,5040 00For
AMG FUNDS47,0000 00For
TIFF INVESTMENT PROGRAM28,5800 00For
BlackRock21,4900 00For
RWC Asset Management LLP8,4940 00For
TRUST FOR PROFESSIONAL MANAGERS04,484 00Against
EA Series Trust2,1230 00For
Advisors' Inner Circle Fund III3140 00For
GuideStone010 00Against

14. REAPPOINTMENT OF MICHAEL DAVIDSON M.D. AS EXECUTIVE DIRECTOR OF THE COMPANY UNTIL THE 2029 ANNUAL GENERAL MEETING.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%
FOR: 70,484,270AGAINST: 9,247,819

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Elect Director: Michael Davidson, M.D.”): 70,484,270 for, 9,247,819 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,169,291 outstanding shares: 63% for, 8% against (71% of the company cast a for/against vote).

The 9 asset managers below cast 98% of the shares they voted on this item FOR (301,191 for, 4,808 against).

FOR 98%
FOR: 301,191 (98.4%)AGAINST: 4,808 (1.6%)
Largest asset managers voting on “REAPPOINTMENT OF MICHAEL DAVIDSON M.D. AS EXECUTIVE DIRECTOR OF THE COMPANY UNTIL THE 2029 ANNUAL GENERAL MEET” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
JPMorgan193,5040 00For
AMG FUNDS47,0000 00For
TIFF INVESTMENT PROGRAM28,5800 00For
BlackRock21,4900 00For
RWC Asset Management LLP8,4940 00For
TRUST FOR PROFESSIONAL MANAGERS04,484 00Against
EA Series Trust2,1230 00For
Advisors' Inner Circle Fund III0314 00Against
GuideStone010 00Against

15. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

1-YEAR 75%ONE YEAR 23%

The 7 asset managers below cast 100% of the shares they voted on this item FOR (64,145 for, 0 against).

FOR: 64,145 (1.9%)1-YEAR: 2,504,884 (75.0%)ONE YEAR: 769,595 (23.1%)
Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
ADAGE CAPITAL PARTNERS GP, L.L.C.00 001-Year
Eversept Partners, LP00 00One Year
JPMorgan00 00One Year
MAVERICK CAPITAL LTD57,3810 00For
RWC Asset Management LLP00 00One Year
BlackRock6,7640 00For
GuideStone00 00One Year

16. Non-binding, advisory vote regarding frequency of future shareholders advisory votes on the compensation of named executive officers. Please vote on this resolution to approve 1 year.

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (345,845 for, 0 against).

FOR: 345,845 (100.0%)
Largest asset managers voting on “Non-binding, advisory vote regarding frequency of future shareholders advisory votes on the compensation of na” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
JENNISON ASSOCIATES LLC314,6150 00For
Wellington31,2300 00For

17. Non-binding, advisory vote regarding frequency of future shareholders advisory votes on the compensation of named executive officers. Please vote on this resolution to approve 2 years.

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

NOT VOTED 100%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

NOT VOTED: 345,845 (100.0%)
Largest asset managers voting on “Non-binding, advisory vote regarding frequency of future shareholders advisory votes on the compensation of na” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
JENNISON ASSOCIATES LLC00 00Not Voted
Wellington00 00Not Voted

18. Non-binding, advisory vote regarding frequency of future shareholders advisory votes on the compensation of named executive officers. Please vote on this resolution to approve 3 years.

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

NOT VOTED 100%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

NOT VOTED: 345,845 (100.0%)
Largest asset managers voting on “Non-binding, advisory vote regarding frequency of future shareholders advisory votes on the compensation of na” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
JENNISON ASSOCIATES LLC00 00Not Voted
Wellington00 00Not Voted

19. Non-binding, advisory vote regarding frequency of future shareholders advisory votes on the compensation of named executive officers. Please vote on this resolution to approve Abstain.

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

NOT VOTED 100%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

NOT VOTED: 345,845 (100.0%)
Largest asset managers voting on “Non-binding, advisory vote regarding frequency of future shareholders advisory votes on the compensation of na” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
JENNISON ASSOCIATES LLC00 00Not Voted
Wellington00 00Not Voted

20. Adopt Financial Statements and Statutory Reports

CORPORATE GOVERNANCE

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (8,504 for, 0 against).

FOR: 8,504 (100.0%)
Largest asset managers voting on “Adopt Financial Statements and Statutory Reports” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RWC Asset Management LLP8,4940 00For
GuideStone100 00For

21. Approve Discharge of Directors

CORPORATE GOVERNANCE

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (8,504 for, 0 against).

FOR: 8,504 (100.0%)
Largest asset managers voting on “Approve Discharge of Directors” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RWC Asset Management LLP8,4940 00For
GuideStone100 00For

22. Authorize Repurchase of Up to 10 Percent of Issued Share Capital

CAPITAL STRUCTUREMajority of the votes cast: yes

85% Majority: yes · of votes cast

FOR 85%AGAINST 15%
FOR: 71,365,533AGAINST: 12,226,858

NewAmsterdam Pharma Company N.V.’s own tally for this item (“Proposal 7. The Company's shareholders approved the extension of authorization for the Board to acquire ordinary shares and depository receipts for ordinary shares in the Company's capital.”): 71,365,533 for, 12,226,858 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 112,169,291 outstanding shares: 64% for, 11% against (75% of the company cast a for/against vote).

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 8,504 against).

AGAINST 100%
AGAINST: 8,504 (100.0%)
Largest asset managers voting on “Authorize Repurchase of Up to 10 Percent of Issued Share Capital” at NewAmsterdam Pharma Company N.V., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RWC Asset Management LLP08,494 00Against
GuideStone010 00Against

Largest NewAmsterdam Pharma Company N.V. shareholders voting in 2024-2025

Ranked by the number of NewAmsterdam Pharma Company N.V. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 112,169,291 shares outstanding at the time of that meeting.

Top NewAmsterdam Pharma Company N.V. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1Frazier Life Sciences Management, L.P. 14.37%
2Capital Group 9.93%
3FCPM III SERVICES B.V. 9.48%
4Bain Capital Life Sciences Investors, LLC 9.34%
5RA CAPITAL MANAGEMENT, L.P. 7.69%
6VIKING GLOBAL INVESTORS LP 6.22%
7DEERFIELD MANAGEMENT COMPANY, L.P. 4.67%
8Medicxi Ventures Management (Jersey) Ltd 2.56%
9Wellington 2.55%
10JENNISON ASSOCIATES LLC 2.48%

Reported NewAmsterdam Pharma Company N.V. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

NewAmsterdam Pharma Company N.V. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
James N. Topper, M.D., Ph.D. 14.64% DEF14A
Capital World Investors 10.87% 13G
ForGrowth NAP B.V. 8.31% 13D
Frazier Life Sciences Public Fund, L.P. 7.69% 13D
Frazier Life Sciences X, L.P. 6.53% 13D
Michael Davidson, M.D. 3.98% DEF14A
VIKING GLOBAL INVESTORS LP 3.75% 13G
Wellington Management 3.16% 13F
John Kastelein, M.D., Ph.D. FESC 1.88% DEF14A
BCLS Fund III Investments, LP 1.84% 13D

Percentages above are of 112,169,291 shares outstanding, as reported by NewAmsterdam Pharma Company N.V. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NewAmsterdam Pharma Company N.V.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At NewAmsterdam Pharma Company N.V.'s shareholder meeting held 2025-06-04, in the 2024-2025 proxy season, 118 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,113 separate fund positions. Their filings are grouped here into 22 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Non-binding, advisory vote to approve the 2024 compensation of named executive officers. — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: NewAmsterdam Pharma Company N.V.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-06.

NewAmsterdam Pharma Company N.V. proxy season coverage: 2024-2025 (this page) · 2025-2026.